Sleep apnea in acromegaly: A review on prevalence, pathogenetic aspects and treatment

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 1, 2012, Pages 55-62

  Dav, Maria Vittoria ^a   Giustina, Andrea ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

acromegaly; diabetes mellitus; GH; IGF 1; pegvisomant; sleep apnea; somatostatin analogs

Indexed keywords

PEGVISOMANT;

ACROMEGALY; CRANIOFACIAL MALFORMATION; DISEASE SEVERITY; HUMAN; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP APNEA SYNDROME; SURVIVAL; UPPER RESPIRATORY TRACT;

EID: 82955193678     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.82     Document Type: Review

References (61)

1. Somers VK, White DP, Amin R et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association council for high blood pressure research professional education committee, Council on clinical cardiology, Stroke council, and Council on cardiovascular nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 118(10), 1080-1111 (2008).
2. Giustina A, Casanueva FF, Cavagnini F et al. Consensus: diagnosis and treatment of acromegaly complications. J. Endocrinol. Invest. 26(12), 1242-1247 (2003).
3. Colao A, Pivonello R, Mazzullo P et al. Severe systemic complications of acromegaly. J. Endocrinol. Invest. 28(Suppl.5), 65-77 (2005).
4. Martin JM, Carrizo SJ, Vincente E, Agust AG. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365, 1046-1053 (2005).
5. Yaggi HK, Concato JK, Kerman WN et al. Obstructive sleep apnoea as a risk factor for stroke and death. N. Engl. J. Med. 353, 2034-2041 (2005).
6. Perks WH, Horrocks PM, Cooper RA et al. Sleep apnoea in acromegaly. Br. Med. J. 280(6218), 894-897 (1980).
7. Hart TB, Radow SK, Blackard WG et al. Sleep apnoea in active acromegaly. Arch. Intern. Med. 145(5), 865-866 (1985).
8. Lindberg E, Carter N, Gislason T, Janson C. Role of snoring and daytime sleepiness in occupational accidents. Am. J. Respir. Crit. Care Med. 164, 2031-2035 (2001).
9. Epstein LJ, Kristo D, Strollo PJ et al.; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J. Clin. Sleep Med. 5(3), 263-276 (2009).
10. Davì MV, Dalle Carbonare L, Giustina A et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159, 533-540 (2008).
11. Pekkarinen T, Partinen M, Pelkonen R et al. Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors. Clin. Endocrinol. (Oxf.) 27(6), 649-654 (1987).
12. Pelttari L, Polo O, Rauhala E et al. Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin. Endocrinol. (Oxf.) 43(2), 175-182 (1995).
13. Rosenow F, Reuter S, Deuss U et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin. Endocrinol. (Oxf.) 45(5), 563-569 (1996).
14. Saeki N, Isono S, Nishino T et al. Sleep-disordered breathing in acromegalics-relation of hormonal levels and quantative sleep study by means of bedside oximeter. Endocr. J. 46(4), 585-590 (1999).
15. Tolis G, Angelopoulos NG, Katounda E et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83, 249-257 (2006).
16. Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J. Clin. Endocrinol. Metab. 95, 483-495, (2010).
17. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann. Intern. Med. 115, 527-532 (1991).
18. Fatti LM, Sacchi M, Pincelli AI et al. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 4(4), 259-262 (2001).
19. Weiss V, Sonka K, Pretl M et al. Prevalence of the sleep apnea syndrome in acromegaly population. J. Endocrinol. Invest. 23, 515-519 (2000).
20. Hochban W, Ehlenz K, Conradt R, Brandenburg U. Obstructive sleep apnoea in acromegaly: the role of craniofacial changes. Eur. Respir. J. 14(1), 196-202 (1999).
21. Sze L, Schmid C, Bloch KE et al. Effect of transsphenoidal surgery on sleep apnea in acromegaly. Eur. J. Endocrinol. 156, 321-329 (2007).
22. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 20, 705-706 (1997).
23. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am. J. Respir. Crit. Care Med. 165, 1217-1239 (2002)
24. Bixler EO, Vgontzas AN, Ten Have T et al. Effects of age on sleep apnea in men: I: prevalence and severity. Am. J. Respir. Crit. Care Med. 157, 144-148 (1998).
25. De Menis E, Giustina A, Colao A et al. COM.E.T.A. Italian study group. Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian study group. J. Endocrinol Invest. 34(1), 60-64 (2011). Erratum in: J. Endocrinol. Invest. 34(2), 169 (2011).
26. Kamenicky P, Viengchareun S, Blanchard A et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149, 3294-3305 (2008).
27. Dostalova S, Sonka K, Smahel Z et al. Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly. Eur. J. Endocrinol. 144(5), 491-497 (2001).
28. Van Haute FR, Taboada GF, Corrêa LL et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur. J. Endocrinol. 158, 459-465 (2008).
29. Berg C, Wessendorf TE, Mortsch F et al. Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur. J. Endocrinol. 161(6), 829-835 (2009).
30. Ip MSM, Tan KCB, Peh WCG, Lam KSL. Effects of sandostatin lar on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin. Endocrinol. 55, 477-483 (2001).
31. Isono S, Saeki N, Tanaka A, Nishino T. Collapsibility of passive pharynx in patients with acromegaly. Am. J. Respir. Crit. Care Med. 160(1), 64-68 (1999).
32. Herrmann BL, Wessendorf TE, Ajaj W et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur. J. Endocrinol. 151(3), 309-315 (2004).
33. Shelton KE, Woodson H, Gay S, Suratt PM. Pharyngeal fat in obstructive sleep apnea. Am. Rev. Respir. Dis. 148, 462-466 (1993).
34. Horner RL, Mohiaddin RH, Lowell DG et al. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. Eur. Respir. J. 2, 613-622 (1989).
35. Grunstein RR, Handelsman DJ, Lawrence SJ et al. Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J. Clin. Endocrinol. Metab. 68, 352-358 (1989).
36. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37(1), 67-99 (2008).
37. Grynberg M, Salenave S, Young J, Chanson P. Female gonadal function before and after treatment of acromegaly. Clin. Endocrinol. Metab. 95(10), 4518-4525 (2010).
38. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. J. Appl. Physiol. 99(5), 1998-2007 (2005).
39. Rasche K, Keller T, Tautz B et al. Obstructive sleep apnea and Type 2 diabetes. Eur. J. Med. Res. 15(Suppl. 2), S152-S156 (2010).
40. Adams N, Strauss M, Schluchter M et al. Relation of measures of sleep-disordered breathing to neuropsychological functioning. Am. J. Respir. Crit. Care Med. 163, 1626-1631 (2001).
41. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464), 1046-1053 (2005).
42. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14, 540-545 (1991).
43. Melmed S, Colao A, Barkan A et al. Guidelines for acromegaly management: an update J. Clin. Endocrinol. Metab. 94, 1509-1517 (2009).
44. Giustina A, Chanson P, Bronstein MD et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141-3148 (2010).
45. Gola M, Bonadonna S, Mazziotti G et al. Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest. 29(1), 86-93 (2006).
46. Pokrajac A, Wark G, Ellis AR et al. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin. Endocrinol. (Oxf.) 67(1), 65-70 (2007).
47. Mickelson SA, Rosenthal LD, Rock JP et al. Obstructive sleep apnea syndrome and acromegaly. Otolaryngol. Head Neck Surg. J. 111(1), 25-30 (1994).
48. Main G, Borsey DQ, Newton RW. Successful reversal of sleep apnoea syndrome following treatment for acromegaly, confirmed by polygraphic studies. Postgrad. Med. J. 64(758), 945-946 (1988).
49. Piper JG, Dirks BA, Traynelis VC, VanGilder JC. Perioperative management and surgical outcome of the acromegalic patient with sleep apnea. Neurosurgery 36(1), 70-74; Discussion 74-75 (1995).
50. Chanson P, Timsit J, Benoit O et al. Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet 1, 1270-1271 (1986).
51. Leibowitz G, Shapiro MS, Salameh M, Glaser B. Improvement of sleep apnoea due to acromegaly during short-term treatment with octreotide. J. Intern. Med. 236, 231-235 (1994).
52. Liao P, Yegneswaran B, Vairavanathan S et al. Postoperative complications in patients with obstructive sleep apnea: a retrospective matched cohort study. Can. J. Anaesth. 56(11), 819-828 (2009).
53. Buyse B, Michiels E, Bouillon R et al. Relief of sleep apnoea after treatment of acromegaly: report of three cases and review of the literature. Eur. Respir. J. 10(6), 1401-1404 (1997).
54. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somtatostatin analog, on sleep apnea in patients with acromegaly. Ann. Inter. Med. 121(7), 478-483 (1994).
55. Grunstein RR, Ho KY, Berthon-Jones M et al. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am. J. Respir. Crit. Care Med. 150(2), 496-502 (1994).
56. Melmed S, Casanueva F, Cavagnini F et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153(6), 737-740 (2005).
57. Giustina A, Bronstein MD, Casanueva FF et al. Current management practices for acromegaly: an international survey. Pituitary 14(2), 125-133 (2011).
58. Becker HF, Jerrentrup A, Ploch T et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107, 68-73 (2003).
59. Harbison J, O'Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest 118, 591-595 (2000).
60. Fleetham J, Ayas N, Bradley D et al. Sleep disordered breathing committee. Canadian thoracic society guidelines: diagnosis and treatment of sleep disordered breathing in adults. Can. Respir. J. 13(7), 387-392 (2006).
61. Maison P, Tropeano AI, Macquin-Mavier I et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. Clin. Endocrinol. Metab. 92(5), 1743-1747 (2007).